Uncovering causal gene-tissue pairs and variants: A multivariable TWAS method controlling for infinitesimal effects

Yihe Yang[1], Noah Lorincz-Comi[1], Xiaofeng Zhu[1]

[1]Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA

Corresponding author: X. Zhu. xxz10@case.edu

Abstract

Transcriptome-wide association studies (TWAS) are commonly used to prioritize causal genes underlying associations found in genome-wide association studies (GWAS) and have been extended to identify causal genes through multivariable TWAS methods. However, recent studies have shown that widespread infinitesimal effects due to polygenicity can impair the performance of these methods. In this report, we introduce a multivariable TWAS method named Tissue-Gene pairs, direct causal Variants, and Infinitesimal effects selector (TGVIS) to identify tissue-specific causal genes and direct causal variants while accounting for infinitesimal effects. In simulations, TGVIS maintains an accurate prioritization of causal gene-tissue pairs and variants and demonstrates comparable or superior power to existing approaches, regardless of the presence of infinitesimal effects. In the real data analysis of GWAS summary data of 45 cardiometabolic traits and expression/splicing quantitative trait loci (eQTL/sQTL) from 31 tissues, TGVIS is able to improve causal gene prioritization and identifies novel genes that were missed by conventional TWAS.

Introduction

Over the past two decades, genome-wide association studies (GWAS) have identified thousands of genetic variants associated with complex traits[1–3]. However, most GWAS signals are detected in non-coding regions and have been shown to have complex regulatory landscapes across different tissues and cell types[4], making it challenging to pinpoint causal variants and genes driving these GWAS signals. Joint GWAS and expression quantitative trait loci (eQTL) data analysis methods, such as colocalization[5], transcriptome-wide association studies (TWAS)[6], and *cis*-Mendelian randomization (*cis*-MR)[7], have been developed to prioritize causal genes at GWAS loci[8]. Colocalization simultaneously examines the expression of a gene and a trait to determine whether they share common causal genetic variants at a locus[5]. Both TWAS and *cis*-MR assume a causal diagram where eQTLs regulate tissue-specific gene expression that subsequently affects a trait, and they identify these tissue-specific causal genes by testing the significance of the causal effect estimates. Furthermore, these methods have been extended to a broader range of molecular phenotypes, such as splicing events[9] and protein abundance[10], with regulatory QTLs being splicing QTLs (sQTLs) and protein QTLs (pQTLs), which we call xQTLs in general.

Nevertheless, colocalization, TWAS, and *cis*-MR are all univariable methods that statistically measure the marginal correlations of genetic effect sizes between a trait and a tissue-specific expression of a gene. Non-causal gene-tissue pairs may be falsely detected by these univariable methods due to the *cis*-gene-tissue co-regulations with causal gene-tissue pairs[8,11,12]. The underlying mechanism may come in the following respects. The tissue-specific eQTLs of a causal gene are often in linkage disequilibrium (LD) with (1) the eQTLs of nearby non-causal genes[13] and (2) the eQTLs of causal genes expressed in non-causal tissues[14]. In addition, some

variants can influence a trait independently of causal gene-tissue pairs, which are frequently

denoted as direct causal variants[13] and horizontal pleiotropy[15].

Multivariable TWAS methods, such as causal TWAS (cTWAS)[13] and Tissue-Gene Fine-

Mapping (TGFM)[14], have been proposed to address these issues. Specifically, cTWAS identifies

causal genes and direct causal variants among multiple candidates using the sum of single effects

(SuSiE)[16,14] by examining tissues separately. TGFM extends cTWAS to allow multiple tissues to

be analyzed simultaneously and can identify the trait-relevant tissues beyond the causal variants

and genes. However, Cui et al.[17] recently reported that current Bayesian fine-mapping methods,

including SuSiE[16,18] and FINEMAP[19], have a high replication failure rate (RFR) in practice. Cui

et al.[17] discovered that the widespread infinitesimal effects, which may stem from the

polygenicity of complex traits, are the sources of the high RFR, and accounting for the

infinitesimal effects can reduce the RFR and improve statistical power. Similarly, the

polygenicity can also lead to inflating the test statistics in standard TWAS[20] and traditional

linkage studies[21]. Thus, due to the lack of modeling infinitesimal effects, it is expected that

cTWAS and TGFM can be vulnerable to spurious prioritization and reduced statistical power.

We present the Tissue-Gene pair, direct causal Variants, and Infinitesimal effect Selector

(TGVIS), a multivariable TWAS method to identify causal gene-tissue pairs and direct causal

variants while incorporating infinitesimal effects. TGVIS employs SuSiE[16,14] for fine-mapping

causal gene-tissue pairs and direct causal variants, and uses restricted maximum likelihood

(REML)[22] to estimate the infinitesimal effects. In addition, we introduce the Pratt index[23] to rank

the importance for improving the prioritization of causal genes and variants. We applied TGVIS

to identify causal *cis*-gene-tissue pairs and direct causal variants for 45 cardiometabolic traits

using GWAS datasets with the largest sample sizes to date[3,24–32], by incorporating the eQTL and

sQTL summary statistics from 28 tissues from genotype-tissue expression (GTEx)[12], and the

eQTL summary statistics of kidney tubulointerstitial[33], kidney glomerular[33], and pancreatic

islets[34] tissues. We summarized the causal gene-tissue pairs and direct causal variants,

highlighted the pleiotropic effects at the gene-tissue level, and demonstrated the different

functional activity[35] of eQTLs/sQTLs mediated through gene-tissues and the direct causal

variants. Moreover, we mapped the trait-relevant major tissues and demonstrated the

enrichments of genes identified by TGVIS in terms of colocalization[5], on the silver standard of

lipid genes[13], FDA-approved drug-target genes[36], and genes detected through pQTL summary

data[10]. Our study reveals a broader picture of gene and tissue co-regulations, which can provide

novel biological insights into complex traits.

Results

Overview of method

Figure 1A illustrates the causal diagram assumed in this report. Specifically, we hypothesize that

a set of xQTLs influence the products of genes (e.g., expressions and splicing events) at a locus.

Gene co-regulation[8,12], i.e., the correlation of xQTL effects among multiple gene products, can

emerge due to shared xQTLs or being in LD among them. Meanwhile, tissue co-regulation[11,37,38],

defined as the correlation of gene expression across multiple tissues, can arise because of the

same mechanism. In the gene and tissue co-regulation network, certain gene-tissue pairs directly

influence a trait without mediation by other gene-tissue pairs, which are referred to as causal

gene-tissue pairs. In addition, some genetic variants may directly influence the trait, which we

consider as direct causal variants. Besides these direct causal variants which have relatively large

effects, we assume there are polygenic or infinitesimal effects that can be modeled through a

normal distribution with mean zero and small variance[17] (**Method**).

The curse of dimensionality poses a substantial challenge in the multivariable TWAS model.

Figure 1B illustrates this challenge by an example of the association evidence with low-density

lipoprotein cholesterol (LDL-C)[1] at the *PCSK9* locus, where dozens of coding genes and long

non-coding ribonucleic acids (RNAs) are located, along with multiple potential direct causal

variants. Conventional statistical methods cannot precisely identify causal gene-tissue pairs and

variants because there are many correlated candidates which frequently range from hundreds to

thousands[16]. The proposed TGVIS enables to overcome the curse of dimensionality. **Figure 1C**

describes the workflow of TGVIS, where the inputs are the GWAS summary statistics of a

trait, xQTL summary statistics of gene-tissue pairs, and a reference LD matrix of the

variants at the locus. TGVIS utilizes a profile-likelihood approach to estimate the causal

effects of gene-tissue pairs and directly causal variant effects with SuSiE[16,18] and model the

infinitesimal effects via REML[22]. This profile-likelihood iterates until all estimates are

converge. The detailed statistical modeling and computation for TGVIS are described in the

Methods and the **Supplementary Materials**.

In practice, another challenge arises when selecting a causal gene-tissue pair based solely on its

posterior inclusion probability (PIP) because many gene-tissue pairs share the same sets of

xQTLs at a locus, making them statistically indistinguishable. SuSiE groups these pairs into a

credible set during fine-mapping and introduces a single effect to describe the contributions of

the variables in the same credible set. Therefore, all inferences should be made based on the

single effects defined by SuSiE's credible sets. To quantify the contribution of each gene-tissue

pair and direct causal variant, we introduce the Pratt index[23] as a metric parallel to PIP. While

PIP measures the significance of variables from a Bayesian viewpoint, the Pratt index quantifies

their predictive importance. In the application, we calculated the cumulative Pratt index of

variables in a 95% credible set (CS-Pratt) and filtered out the credible sets with low CS-Pratt

values (**Methods** and **Supplementary Materials**). We observed that this procedure improved

the precision of causal gene and variant identification.

Simulation

We compared the TGVIS with 4 multivariable MR and TWAS methods: cisIVW[39], Grant2022[40],

cTWAS[13], and TGFM[14]. We applied the following criteria for determining the causality: the

95% credible set for TGVIS, TGFM, and cTWAS; $P < 0.05$ for cisIVW; and selection by lasso

in the Grant2022. We did not consider univariable methods because of their high type-I error

rates when the goal is to identify causal genes, given that xQTL effect sizes for multiple genes

are often correlated[13]. Detailed information on the settings and results can be found in the

Methods and **Supplementary Materials**.

We first assessed the accuracy of causal effect estimation for gene-tissue pairs. When

infinitesimal effects were absent, TGVIS showed a mean square error (MSE) for causal effect

estimates similar to that of cTWAS, and TGFM, while both cisIVW and Grant2022 exhibited

substantially larger MSE (as shown in the left two panels in **Figure 2A**). However, when

infinitesimal effects were present, TGVIS demonstrated a visibly lower MSE compared to the

other methods, with cTWAS and TGFM showing approximately 32% higher MSE than TGVIS

(as shown in the right two panels in **Figure 2A**). These results indicate that TGVIS generally

outperforms its competitors by accounting for infinitesimal effects.

We then compared the true negative rate (TNR) and true positive rate (TPR) of these five

methods. A true negative is defined as a method that correctly identifies all 98 non-causal gene-

tissue pairs. Similarly, a true positive is defined as a method that correctly identifies the 2 causal

gene-tissue pairs. Across all the scenarios (**Figure 2B**), TGVIS achieved the highest TNR, with

an average of 0.614, followed by TGFM and cTWAS, with average TNRs of 0.513 and 0.499,

respectively. *Cis*IVW and Grant2022 performed worst, with averages TNR of 0.064 and 0.013,

respectively, indicating that these two methods are prone to identifying a substantial number of

false positive gene-tissue pairs. On the other hand, TGVIS exhibited a similar TPR (average

TPR = 0.667) as TGFM, cTWAS, and *cis*IVW (average TPRs of 0.649, 0.667, and 0.661,

respectively), while Grant2022 had the highest TPR (averages TPR= 0.831) (**Figure 2C**), which

is not surprising given that Grant2022 also has lowest TNR.

We further assessed the performance in detecting direct causal variants. In scenarios where no

direct causal variants were present, the TGVIS identified fewer direct causal variants, with an

average number of 0.92, compared to 2.39 for TGFM and 2.38 for cTWAS (**Figure 2D**). When

there were two direct causal variants present, TGVIS identified an average of 2.86 direct causal

variants, compared to 3.58 for both cTWAS and TGFM. The averaged correlations between the

estimated and true direct causal effects across simulations were high for all three methods

(**Figure 2E**). However, predicting infinitesimal effects remains challenging, as evidenced by an

average correlation of 0.663 between the predicted and true infinitesimal effects in TGVIS

(**Figure 2F**).

Searching potentially causal gene-tissue pairs and variants for 45 cardiometabolic traits

We systematically analyzed 45 cardiometabolic traits and eQTL/sQTL summary statistics (**Table**

S1-S2) to identify potential causal gene-tissue pairs and direct causal variants. For the TVGIS,

we considered whether a gene-tissue pair or direct causal variant was causal if (1) it was within a

95% credible set and (2) had a CS-Pratt > 0.15. The criteria of CS-Pratt >0.15 was established

based on the empirical evidence (**Methods**). For TGFM, we followed the authors'

recommendation of considering individual PIP > 0.5 as indicative of causality. Additionally, we

did not compare with cTWAS because it analyzes tissues separately[13].

TGVIS and TGFM identified a median of 119.5 and 227.5 causal gene-tissue pairs, and 42 and

183 causal variants per trait (**Figure 3A, Table S3-S6**), respectively. Additionally, TGVIS

detected a median of 0.313 causal gene-tissue pairs and 0.115 direct causal variants per locus,

while TGFM identified a median of 0.469 causal gene-tissue pairs and 0.466 direct causal

variants per locus (**Figure 3C**). Overall, TGVIS reduced the number of causal gene-tissue pairs

by a median of 55.7% and the number of direct causal variants by 24.5% per trait compared to

TGFM, representing the improved resolution of TGVIS over TGFM.

We would expect that causal gene-tissue pairs detected by TGVIS and TGFM would likely be

included among those identified by univariable TWAS methods such as S-PrediXcan.

Surprisingly, among the causal pairs identified by TGVIS, a median of 34.3% were undetected

by S-PrediXcan, and this proportion was 60.1% for TGFM (**Figure 3A**, **Table S22**). For

example, TGVIS identified *SCN2A*-Nerve_Tibial as a novel causal gene-tissue pair for 12 traits

(**Figure S37**) but missed by univariable TWAS. In addition, both TGVIS and univariable TWAS

identified *SCN2A*-Nerve_Tibial for type 2 diabetes. Our findings suggest *SCN2A* may regulate a

wide range of metabolic traits. These results indicate that TGVIS not only fine-maps causal

genes detected by TWAS but also uncovers novel genes.

We investigated how many traits can be influenced by a causal gene-tissue pair, reflecting the

pleiotropic effect at the gene-tissue level. Among the causal gene-tissue pairs falling in credible

sets of size less than 2, 22.4% identified by TGVIS and 16.7% by TGFM exhibit pleiotropic

effect (**Figure 3D**, **Table S7-S8**), indicating that many of these causal genes contribute to shared

biological mechanisms across multiple traits.

We further examined whether the direct causal variants and xQTLs mediated by causal gene-

tissue pairs differ in functionality using functional annotations[35] (**Methods)**. Significant

differences were observed between these two types of variants identified by either TGVIS or

TGFM across multiple annotations (**Table S11**). As shown in **Figure 3E** and **3F**, the direct

causal variants generally have higher FathmmXF and h3k9me3 scores than the xQTLs mediated

by causal gene-tissue pairs (Wilcoxon signed-rank test, P<2.2E-16), suggesting distinct

biological mechanisms for many of these variants.

We observed that multiple eGenes and sGenes often shared the same set of variants as their

xQTL, highlighting the importance of making inferences based on credible sets rather than

individual variables. Most credible sets consisted of 2 to 4 gene-tissue pairs (60.5%), although

some credible sets included more than 10 (11.5%) for TGVIS (**Figure 4A, Table S12**). In

comparison, TGFM resulted predominantly featured single gene-tissue pairs (56.0%) and 2 to 4

pairs (41.7%) per credible set (**Figure S18, Table S12**). On the other hand, most of the credible

sets only had one xQTL (66.6%), followed by two xQTLs (12.6%) for TGVIS (**Figure 4B,**

Table S13). As for TGFM, these percentages were 26.9% for one xQTL and 24.4% for two

xQTLs (**Figure S20, Table S13**). These differences arise because TGFM resampled all xQTLs

in the 95% credible sets, typically incorporating more variants, whereas TGVIS applied a stricter

criterion for selecting xQTLs (**Methods**, **Figure S18-S19**).

We investigated the proportions of identified causal eGenes and sGenes for the 45

cardiometabolic traits (**Methods**). TGVIS showed eGenes and sGenes proportions of 58.1% and

41.9%, respectively, while TGFM resulted in 63.5% for eGenes and 36.5% for sGenes (**Figure**

4C, Figure S21). These results align with the proportions observed in the GTEx Consortium

(63% *cis*-eQTL vs. 37% *cis*-sQTL)[12], with TGFM's proportions being slightly closer. A potential

explanation is that TGVIS' eGenes and sGenes were more likely enriched for causal genes

specific to cardiometabolic traits, leading to a slight difference, though this difference is not

substantial.

We calculated the Pratt index of gene-tissue pairs, direct causal variants, and infinitesimal effects

based on its additive property (**Figure 4D, Table S15**), which helps measure the contributions of

these three potentially correlated components (**Methods**). For TGVIS, the median of the Pratt

index was 0.161, 0.059, and 0.182 for gene-tissue pairs, direct causal variants, and infinitesimal

effects, respectively, with a median sum of the Pratt index of 0.403. In comparison, for TGFM,

the median of the Pratt index was 0.145 for gene-tissue pairs and 0.114 for direct causal variants,

with a median sum of the Pratt index of 0.262. These results support the existence of widespread

infinitesimal effects.

Major relevant tissue map of cardiometabolic traits

We searched the major relevant tissues by counting their numbers to the causal gene-tissue pairs

in credible sets identified by TGVIS and TGFM (**Methods**). We ranked the top relevant tissues

according to their contributions and clustered similar traits and tissues based on the similarity of

the identified causal gene-tissue pairs (**Figure 5A-5B, Figure S22-S23**). Overall, we observed

similar major relevant tissues and clustering patterns using both methods, although there were

some notable differences. TGVIS tended to cluster similar traits more closely together than

TGFM. For instance, TGVIS grouped all blood pressure traits into close clusters, placing them

near coronary artery disease (CAD), whereas TGFM positioned systolic and diastolic blood

pressures (SBP and DBP) farther from pulse pressure (PP) and CAD. Similarly, serum lipid traits

were clustered together by TGVIS, but not by TGFM. On the other hand, arterial tissues

consistently emerged as the major tissue for blood pressure traits and CAD, while heart tissues

were the major tissue for the QRS complex, atrial fibrillation, QT interval, and JT interval.

Fibroblasts were highlighted as an important tissue for many traits, aligning with recent findings

about their role in tissue integrity and chronic inflammation, alongside other tissues such as

adipose tissue and liver[41].

We considered several lipids traits, including LDL-C, HDL-C, TC, triglyceride,

apolipoprotein A1 (APOA1), and apolipoprotein B (APOB), as examples to illustrate the

proportional counts of each tissue identified in the credible sets. For HDL-C and triglycerides,

the most relevant tissue was subcutaneous adipose (**Figure 5C**). In contrast, liver tissue was

consistently the most relevant tissue for LDL-C, APOB, and TC, despite the small sample size

for the liver tissue gene expression data[12]. For APOA1, the two most relevant tissues were the

liver and subcutaneous adipose tissue. **Figures S24-S32** display the plots of major tissues for the

rest of the traits. Overall, the TGVIS and TGFM produced in general consistent results.

Evaluation of the identified gene-tissue pairs

To evaluate the accuracy of the prioritization of causal gene-tissue pairs, we first compared the

colocalization evidence of the causal credible sets identified by TGVIS and TGFM through

Coloc-SuSiE[5]. Since a credible set could include multiple tissue-gene pairs, we defined a

colocalization of a credible set in two criteria: (1) the credible set contained at least one gene-

tissue pair that is colocalized with the trait; (2) more than 50% of the gene-tissue pairs in the

credible set were colocalized with the trait (**Method**). TGVIS had much higher proportions of

colocalized credible sets (the median proportions across traits were 93.1% and 77.8% for the two

criteria, respectively) than TGFM (the median proportions across traits were both 40.9% for two

criteria) (**Figure 6A and Table S16-S17**), suggesting a substantial number of causal tissue-gene

pairs identified by TGFM do not have colocalization evidence.

We next followed the previous analysis strategy[13] to assess the causal genes for LDL-C

identified by TGVIS and TGFM. Precision was evaluated using the 69 known lipid-related genes

as the silver standard positive gene set, and nearby genes within a 1MB-radius region as the

negative set, as studied by Zhao et al.[13]. We disregarded the tissue part of the identified causal

gene-tissue pairs and then calculated how many causal genes were within the lists of sliver and

nearby genes. TGVIS demonstrated a precision of 60.0% (9 out of 15), outperforming TGFM,

which had a precision of 37.5% (10 out of 28) (**Table S18** and **Figure S33**).

It is reasonable to assume that causal genes are more likely to be druggable targets. We utilized

the published list of 6,690 FDA/EMA-approved non-cancer drugs (**Table S1** provided by

Trajanoska et al.[36]) to calculate the enrichment of the identified causal genes in the drug list

(**Figure 6B** and **Table S19-S20**). Although the number of causal genes identified by TGVIS in

the drug-targeted gene list was only 74.3% of that identified by TGFM, the enrichment identified

by TGVIS was 1.43 times more than that by TGFM (P = 1.56E-3).

We hypothesized that causal genes detected through eQTLs/sQTLs may be more likely to

demonstrate association evidence in protein data. To test this, we conducted univariable MR

analysis of protein abundances (pGenes) in blood tissue for genes identified by TGVIS and

TGFM, using both *trans-* and *cis*-pQTLs as instrument variables (**Figure 6C** and **Table S21**). On

average, 18.1% of pGenes identified by TGVIS showed significant causal evidence, compared to

13.7% of pGenes for TGFM (P = 3.1E-3). However, this proportion is lower than the estimated

true positive association rate of 27.8% between predicted *cis*-regulated gene expression and

plasma protein abundances[42]. The discrepancy may arise from the fact that pGenes are

influenced by widespread *trans*-pQTLs[10], whereas predicted gene expression is predominantly

contributed by *cis*-eQTLs, and its *trans*-regulated effects are much more difficult to detect. This

result suggests that eGenes/sGenes and pGenes may represent distinct biological processes

related to complex traits[42].

Fine-mapping of causal gene-tissue pairs and variants in GWAS loci

We exemplified four loci associated with LDL-C, CAD, and BMI. The first locus contains the

PCSK9 gene for LDL-C (**Figure 7A**). TGVIS identified three 95% credible sets, including

PCSK9-Whole_Blood and two direct causal variants *rs11591147* and *rs11206517* (**Figure 7B**).

After applying the threshold of CS-Pratt > 0.15, *PCSK9*-Whole_Blood (CS-Pratt = 0.17) and

rs11591147 (CS-Pratt = 0.492) remained. In contrast, TGFM identified nine gene-tissue pairs

and direct causal variants with PIPs > 0.5 (**Figure 7C**), including the *MROH7*-

Esophageal_Mucosa which has no clear connection to the biology of LDL-C. Applying the CS-

Pratt threshold, *PCSK9*-Whole_Blood (CS-Pratt = 0.204) and *rs11591147* (CS-Pratt = 0.524)

remained, consistent with the results yielded by TGVIS. This example demonstrates how TGVIS

reduces false positives by modeling infinitesimal effects and applies the Pratt Index as an

additional criterion.

The second locus contains the *HMGCR* gene causal[43] to LDL-C (**Figure 7D**). TGVIS identified

five 95% credible sets (**Figure 7E**). The first credible set (the darkest green) includes 9 gene-

tissue pairs, such as *HMGCR*-Muscle_Skeletal and five of its sGenes in esophagus mucosa,

nerve tibial, fibroblasts, and adipose visceral, all sharing the same xQTL *rs2112653*. When we

applied the threshold of individual PIP > 0.5, none of the pairs in this credible set were selected

although they were all in a 95% credible set. However, this set had the highest CS-Pratt of 0.322

among the five 95% credible sets. Conversely, TGFM identified *POLK*-Lung (CS-Pratt = 0.684)

but missed the crucial *HMGCR* gene (**Figure 7F**). This is likely a false discovery, as *HMGCR*

inhibitor is a key component of statins, which works by inhibiting HMG-CoA reductase and thus

reduces LDL-C in the blood[43].

In the third example, we focused on the *PHACTR1* locus related to CAD (**Figure 7G**). Both

TGVIS and TGFM identified a major credible set at this locus, including *PHACTR1*-

Artery_Coronary and *PHACTR1*-Artery_Aorta, with CS-Pratt values of 0.632 and 0.612,

respectively (**Figure 7H-7I**). In TGVIS, the individual PIPs of them were both 0.5 and the

cumulative PIP for this credible set was 1. In contrast, TGFM resampled both the eQTL effect

estimates and the PIPs (**Methods**), resulting in a higher individual PIP and Pratt index for

PHACTR1-Artery_Aorta (PIP = 0.597, Pratt = 0.472) than *PHACTR1*-Artery_Coronary (PIP =

0.222, Pratt = 0.053). However, as noted by Strober et al.[14], this resampling process tends to

favor gene-tissue pairs with larger sample sizes, which may explain the exclusion of *PHACTR1*-

Artery_Coronary. TGVIS adheres to the original interpretation of SuSiE that the variables within

a credible set cannot be distinguished from the available data.

The final exemplary locus is the *FTO* locus associated with BMI (**Figure 7J**). TGVIS identified

only two direct causal variants *rs7206790* and *rs3751813* and did not find any gene-tissue pairs

at this locus (**Figure 6K**). In contrast, TGFM identified four gene-tissue pairs:

*FTO*_Kidney_Glomerulus, *FTO*_Thyroid, *FTO*_Artery Tibial, and *IRX3*-

Adipose_Subcutaneous, and five direct causal variants (**Figure 7L**). However, the associations

between obesity and the expression of the *FTO* gene in the kidney glomerulus, thyroid, and tibial

artery are not well-established in the literature. After applying the Pratt index threshold, only two

direct causal variants *rs7206790* and *rs3751813,* remained, consistent with the result from the

TGVIS. When we reduced the locus radius from 1MB to 500KB and re-ran the analysis, both

TGVIS and TGFM identified the sGene of *FTO*-Pancreas as causal, with CS-Pratt values of

0.345 and 0.407, respectively (**Figure S35**). The sQTLs of this *FTO* sGene are *rs7206790* and

rs11642841, which have been reported by Xu et al.[44]. This example suggests that when applying

multivariable TWAS methods, the size of a *cis*-region can be sensitive and need to be calibrated.

Discussion

In this report, we developed TGVIS to identify causal gene-tissue pairs and direct causal variants

in loci identified through GWAS by integrating xQTL summary statistics. Compared to

cTWAS[13] and TGFM[14], TGVIS not only analyzes multiple tissue-specific xQTL summary data

simultaneously to pinpoint causal gene-tissue pairs and direct causal variants, but also models the

widespread presence of infinitesimal effects underlying polygenic traits to reduce false discovery

rates in detecting causal molecular phenotypes[17]. In addition, TGVIS quantifies the importance

of a causal variable by the Pratt index, which has been well established in statistics and has

recently been applied to estimate the gene-by-environment contribution[23]. Through simulations,

we demonstrated that under the presence of infinitesimal effects, TGVIS has lower MSE and

higher TPR and TNR compared to both cTWAS and TGFM (**Figure 2**). In real data analysis,

TGVIS outperformed TGFM in the following four aspects: (1) identifying more interpretable

major trait-relevant tissues (**Figure 5**); (2) resulting in a higher proportion of colocalized causal

credible sets (93.1% vs 40.9%, **Figure 6A**); (3) achieving notably higher precision in the 'silver

standard' sets of lipids (60.0% vs 37.5%, **Table S15**); and (4) demonstrating significantly greater

enrichment evidence based on druggable genes (1.43 times, **Figure 6B**) and causal proteins (1.31

times, **Figure 6C**).

Our analysis of 45 cardiometabolic traits provides several key insights. First, we identified a

median of 34.3% causal gene-tissue pairs that were missed in univariable TWAS analysis,

suggesting that TGVIS is able to identify novel genes besides fine-mapping the genes detected

by conventional TWAS (**Figure 3A**), representing a significant advance in TWAS. Second, we

observed that infinitesimal effects can make a substantial contribution to local genetic variation

of traits besides the gene-tissue pairs and direct variant (**Figure 4D**), which is consistent with

recent studies[17,21,45]. Beyond underlying biological mechanisms such as the polygenicity of

human complex traits, the emergence of infinitesimal effects may also be attributed to non-

biological factors, particularly estimation errors in the LD matrix, xQTL effect sizes, and trait

GWAS imputation (**Method**). Both empirical observations and theoretical investigation

underscore the importance of including infinitesimal effects in future genetic researches and

methodological developments. Third, our study indicates that a significant proportion of causal

gene-tissue pairs (22.4%) exhibit pleiotropic effects at the gene-tissue level, suggesting shared

biological mechanisms across multiple traits (**Figure 3D, Table S7-S8**). Fourth, our findings

suggest that for most traits, only a limited number of relevant major tissues are involved (**Figure

4A**), implying that concentrating multi-omics data analyses on these relevant major tissues can

be more powerful and efficient, as well as it can make the findings more biologically

interpretable. For example, when the analysis is focused on the four major blood-pressure-

relevant tissues, i.e., adrenal gland, artery, heart, and kidney, it leads to the identifications of

more causal gene-tissue pairs, with an increased Pratt index for blood pressure traits[46]. Fifth, our

results indicate that only 18.1% of causal genes from eQTL/sQTL analyses also show causal

evidence in univariable MR using pQTL summary data (**Figure 6C**), suggesting that gene

expressions and protein abundance represent distinct biological processes in complex traits[42].

Finally, we identified an average of 0.304 causal gene-tissue pairs per locus and failed to identify

any causal gene-tissue pairs in many GWAS loci (**Figure 3A**), which is consistent with the

recent study showing that the GWAS and eQTL studies are systematically biased toward

different types of variants[4]. Interestingly, the eQTLs/sQTLs of causal gene-tissue pairs and direct

causal variants have substantially different functional annotations (**Figure 3E-3F, Table S11**),

warranting further investigation.

Our study has some limitations. Due to the data and computational constraints, we only analyzed

genes using *cis*-eQTL/sQTL summary statistics, limiting our ability to distinguish between genes

that share *cis*-eQTLs/sQTLs, which may lead to false discoveries. This issue could potentially be

addressed by incorporating *trans*-eQTLs/sQTLs, although this would require much larger sample

sizes. In addition, we observed that a credible set often contains 2-4 gene-tissue pairs (**Figure

3C**), likely due to the small sample size in the GTEx data, which results in only 1 or 2

eQTL/sQTL for most gene-tissue pairs (**Figure 4B**). In other words, while TGVIS was able to

narrow down to a range of causal gene-tissue pairs, it could not always pinpoint the exact causal

pair(s) in some loci. Incorporating external information, such as colocalization evidence with

TGVIS, may aid in distinguishing these pairs[47]. Furthermore, our eQTL/sQTL analysis relies on

bulk tissue expression data, which may limit our ability to identify cell-type-specific causal

genes[48]. For example, recent studies increasingly suggest that *FTO* may not be the causal gene

for BMI; instead, experimental evidence indicates that *IRX3* and *IRX5* are the causal genes[49].

However, the causality of *IRX3* and *IRX5* was observed in experiments using preadipocytes,

rather than bulk subcutaneous adipose tissue, which may explain why TGVIS failed to identify

these genes (**Figure S36**). Moreover, we used the Pratt index[23] to rank the importance of

variables, but it has inherent statistical limitations[23]. In simulations, the Pratt index slightly

underestimates the true contribution, although this underestimation becomes negligible as the

sample size increases (**Figure S1-S8**). In real data analysis, we used an empirical cutoff learned

by K-means (CS-Pratt = 0.15) to extract important causal variables, which gives us higher

precision but may have potentially hindered the discovery of causal gene-tissue pairs with small

to moderate causal effects. Last, as suggested in previous studies[14], the inference of causality

based on statistical methods comes with a caveat, assuming no model misspecification and no

potential causal elements are missing from the model.

In summary, our developed TGVIS and accompany software pipeline provide a valuable tool in

fine-mapping and interpreting GWAS findings.

Methods

Multivariable TWAS model

The causal diagram shown in **Figure 1A** can be described by the following multivariable TWAS

model:

397
$$y = \sum_{j=1}^{J} \sum_{t=1}^{T} X_{jt}\, \theta_{jt} + \mathbf{G}^{\mathsf{T}}(\boldsymbol{\gamma} + \boldsymbol{\upsilon}) + \varepsilon, \quad (1)$$

where y is a trait, X_{jt} is the jt^{th} gene-tissue pair, $\mathbf{G} = (G_1, \ldots, G_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector of

genetic variants in the *cis*-region, $\boldsymbol{\theta} = (\theta_{11}, \ldots, \theta_{JT})^{\mathsf{T}}$ is an $(JT \times 1)$ vector of causal effects with

θ_{jt} being the causal effect of the (j, t)th tissue-gene pair, $\boldsymbol{\gamma} = (\gamma_1, \ldots, \gamma_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector

of direct causal effects, $\boldsymbol{\upsilon} = (\upsilon_1, \ldots, \upsilon_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector of infinitesimal effects, and ϵ is

the random error. Let $\boldsymbol{\beta}_{jt} = (\beta_{jt1}, \ldots, \beta_{jtM})^{\mathsf{T}}$ is an $(M \times 1)$ vector of the *cis*-eQTL effects of JT

tissue-gene pairs. Then we have

404
$$X_{jt} = \boldsymbol{\beta}_{jt}^{\mathsf{T}} \mathbf{G} + \epsilon_{jt}, \quad (2)$$

405   where ϵ_{jt} is the noise of the jt^{th} gene-tissue pair. The reduced form of (1) is then given by:

406
$$y = \mathbf{G}^{\mathsf{T}} \left(\sum_{j=1}^{J} \sum_{t=1}^{T} \boldsymbol{\beta}_{jt}\, \theta_{jt} + \boldsymbol{\gamma} + \boldsymbol{\upsilon} \right) + \epsilon, \quad (3)$$

407   where mathematically $\epsilon = \varepsilon + \sum_{j=1}^{J} \sum_{t=1}^{T} \epsilon_{jt}\, \theta_{jt}$.

408   An alternative version of (1) based on summarized statistics[50] is:

409
$$\hat{\mathbf{a}} \sim \mathcal{N}\left(\mathbf{R}\left(\sum_{j=1}^{J}\sum_{i=1}^{T}\boldsymbol{\beta}_{jt}\,\theta_{jt} + \boldsymbol{\gamma} + \boldsymbol{\upsilon}\right), \sigma_{\alpha}^{2}\mathbf{R}\right), \quad (3)$$

410   where $\hat{\mathbf{a}} = (\hat{a}_1, \ldots, \hat{a}_M)^{\mathsf{T}}$ represents the GWAS effects of the outcome, $\mathbf{R}$ is an $(M \times M)$ LD

411   matrix of the M variants, and σ_{α}^{2} is the variance of this model. The eQTL effect vector $\boldsymbol{\beta}_{jt}$

412   follows the model based on summarized statistics below:

413
$$\hat{\mathbf{b}}_{jt} \sim \mathcal{N}\left(\mathbf{R}\boldsymbol{\beta}_{jt}, \sigma_{\beta_{jt}}^{2}\mathbf{R}\right), \quad (5)$$

where $\hat{\mathbf{b}}_{jt} = (\hat{b}_{jt1}, \ldots, \hat{b}_{jtM})^{\mathsf{T}}$ represents the marginal *cis*-eQTL effect estimates for the jt^{th}

tissue-gene pair, and $\sigma_{\beta_{jt}}^{2}$ denotes the variance of this model.

To resolve this curse of dimensionality, we utilized the three sparsity conditions that are

commonly assumed in current fine-mapping methods[16,19]: (SP1) one or small number of variants

causally contribute to tissue or cell-type specific gene expression[12]; (SP2) one or small number

of gene-tissue pairs causally contribute to the trait[13,14]; (SP3) one or small number of direct

causal variants exist with relatively large effect sizes[13,14]. In terms of statistical model: SP1

corresponds to $\boldsymbol{\beta}_{jt}$ being sparse for all j and t; SP2 corresponds to $\boldsymbol{\theta}$ being sparse; SP3

corresponds to $\boldsymbol{\gamma}$ being sparse. In addition, we incorporated that variants can have infinitesimal

effects: $\boldsymbol{\upsilon}$ is normally distributed with a mean 0 and a small, unknown variance [17]. To our best

knowledge, infinitesimal effects have not been modeled in current multivariable TWAS

methods.

Estimation of *cis*-regulatory effect

TGVIS first applies SuSiE[18] to estimate the non-zero eQTL effect for each gene-tissue pair,

based on the fine-mapping model (Equation 5). Specifically, we set $L = 3$ for each pair and

determined the non-zero cis-regulatory effects based on two criteria: (1) if they are within any

95% credible set and their PIPs exceeds 0.25, and (2) if their individual PIPs are greater than 0.5.

The rationale behind this approach is that SuSiE's 95% credible set can sometimes include too

many weakly correlated variants (even after removing highly correlated ones using LD

clumping), leading to low PIPs for each variant. Therefore, we used a moderate threshold to filter

out credible sets with too many variants. Additionally, due to the low power of detection, the

maximum PIP of credible sets might fall below 0.95, so we retained variants with individual

PIPs greater than 0.5. Since a locus often contains over 10,000 gene-tissue pairs (mostly sGenes),

dynamically selecting using BIC would be computationally burdensome. Additionally, with

GTEx sample sizes under 200, only 1-2 gene-tissue pairs can be identified for most gene-tissue

pairs. Therefore, we choose to fix $L = 3$.

Joint modelling of causal tissue-gene pairs, direct causal variants, and infinitesimal effects

using profile likelihood

TGVIS estimates $\boldsymbol{\theta}$, $\boldsymbol{\gamma}$, and $\boldsymbol{\upsilon}$ using a profile likelihood approach. Given the estimate $\boldsymbol{\upsilon}^{(s)}$ from

the sth iteration, we considered the following fine-mapping model:

$$\hat{\mathbf{a}} - \mathbf{R}\boldsymbol{\upsilon}^{(s)} \sim \mathcal{N}\left(\mathbf{R}\boldsymbol{\gamma} + \mathbf{R}\hat{\mathbf{B}}\boldsymbol{\theta}, \sigma_\alpha^2 \mathbf{R}\right), \quad (6)$$

445   where $\hat{\mathbf{B}} = \left(\hat{\boldsymbol{\beta}}_{11}, \ldots, \hat{\boldsymbol{\beta}}_{jt}, \ldots, \hat{\boldsymbol{\beta}}_{JT}\right)$ is an $M \times JT$ matrix consisting of estimated cis-regulatory

446   effects. To update $\boldsymbol{\gamma}$ and $\boldsymbol{\theta}$ simultaneously, we applied the same scheme as cTWAS and TGFM,

447   using the function susie_rss($\cdot$). The input z-score vector is computed as:

448
$$z = \left(\frac{\widehat{\boldsymbol{\beta}}_{11}^\top \widehat{\mathbf{a}}}{\sqrt{\widehat{\boldsymbol{\beta}}_{11}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{11}}}, \cdots, \frac{\widehat{\boldsymbol{\beta}}_{JT}^\top \widehat{\mathbf{a}}}{\sqrt{\widehat{\boldsymbol{\beta}}_{JT}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{JT}}}, \hat{a}_1, \cdots, \hat{a}_M \right)^\top, \quad (7)$$

449   and the other elements of input correlation matrix are computed as:

450
$$\mathrm{cor}\big(\mathbf{G_i}\widehat{\boldsymbol{\beta}}_{jt}, \mathbf{G_i}\widehat{\boldsymbol{\beta}}_{j't'}\big) = \frac{\widehat{\boldsymbol{\beta}}_{jt}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{j't'}}{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{jt}} \sqrt{\widehat{\boldsymbol{\beta}}_{j't'}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{j't'}}},$$

451
$$\mathrm{cor}\big(\mathbf{G_i}\widehat{\boldsymbol{\beta}}_{jt}, \mathbf{G_i}\big) = \frac{\mathbf{R}\widehat{\boldsymbol{\beta}}_{jt}}{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^\top \mathbf{R} \widehat{\boldsymbol{\beta}}_{jt}}}, \qquad \mathrm{cor}(\mathbf{G_i}) = \mathbf{R}, \quad (8)$$

452   The outputs are denoted as $\boldsymbol{\gamma}^{(s+1)}$ and $\boldsymbol{\theta}^{(s+1)}$.

453   Next, we consider the following model:

454
$$\widehat{\mathbf{a}} - \boldsymbol{\eta}^{(s+1)}|\boldsymbol{\upsilon} \sim \mathcal{N}(\mathbf{R}\boldsymbol{\upsilon}, \sigma_\alpha^2 \mathbf{R}), \quad \upsilon \sim \mathcal{N}(0, \sigma_\upsilon^2 \mathbf{I}), \quad (9)$$

455   where $\boldsymbol{\eta}^{(s+1)} = \mathbf{R}\big(\widehat{\mathbf{B}}\boldsymbol{\theta}^{(s+1)} + \boldsymbol{\gamma}^{(s+1)}\big)$. The penalized quasi-likelihood (PQL) of $\boldsymbol{\upsilon}$ is

456
$$\boldsymbol{\upsilon}^{(s+1)} = \underset{\boldsymbol{\upsilon}}{\mathrm{argmin}} \left\{ \big(\widehat{\mathbf{a}} - \boldsymbol{\eta}^{(s+1)} - \mathbf{R}\boldsymbol{\upsilon}\big)^\top \mathbf{R}^{-1}\big(\widehat{\mathbf{a}} - \boldsymbol{\eta}^{(s+1)} - \mathbf{R}\boldsymbol{\upsilon}\big) + \frac{\sigma_\alpha^{(s)2}}{\sigma_\upsilon^{(s)2}} \parallel \boldsymbol{\upsilon} \parallel_2^2 \right\}, \quad (10)$$

457   which results in

458
$$\boldsymbol{\upsilon}^{(s+1)} = \left(\mathbf{R} + \frac{\sigma_\alpha^{(s)2}}{\sigma_\upsilon^{(s)2}} \mathbf{I} \right)^{-1} \big(\widehat{\mathbf{a}} - \boldsymbol{\eta}^{(s+1)}\big), \quad (11)$$

where $\sigma_\alpha^{(s)2}$ is the current variance estimate. The variance $\sigma_\upsilon^{(s)2}$ is updated by REML:

$$\sigma_v^{(s+1)2} = \underset{\sigma_v^2}{\operatorname{argmin}} \left\{ \frac{\parallel \mathbf{v}^{(s+1)} \parallel_2^2}{\sigma_v^2} + M\log(\sigma_v^2) + \operatorname{logdet}\left(\frac{1}{\sigma_\alpha^{(s)2}}\mathbf{R} + \frac{1}{\sigma_v^{(s)2}}\mathbf{I} \right) \right\}, \quad (12)$$

which simplifies to

$$\sigma_v^{(s+1)2} = \frac{1}{M} \parallel \mathbf{v}^{(s+1)} \parallel_2^2 + \frac{1}{M}\operatorname{tr}\left(\left(\mathbf{R} + \frac{\sigma_\alpha^{(s)2}}{\sigma_v^{(s)2}}\mathbf{I} \right)^{-1} \right), \quad (13)$$

where M is the number of variants. We replace σ_v^2 in the last term by its current estimate $\sigma_v^{(s)2}$ to

obtain a close-form expression. Note that in Equation (13), $\frac{\sigma_\alpha^{(s)2}}{\sigma_v^{(s)2}}$ is usually replaced by $\frac{1}{\sigma_v^{(s)2}}$ to

avoid non-identifiability issues[22].

When the profile likelihood converges, TGVIS estimates σ_α^2 as follows:

$$\sigma_\alpha^{(s+1)2}$$

$$= \frac{1}{M}\left(\hat{\mathbf{a}} - \mathbf{R}\big(\hat{\mathbf{B}}\boldsymbol{\theta}^{(s+1)} + \boldsymbol{\gamma}^{(s+1)} + \mathbf{v}^{(s+1)}\big) \right)^{\mathsf{T}} \mathbf{R}^{-1}\left(\hat{\mathbf{a}} - \mathbf{R}\big(\hat{\mathbf{B}}\boldsymbol{\theta}^{(s+1)} + \boldsymbol{\gamma}^{(s+1)} + \mathbf{v}^{(s+1)}\big) \right). \quad (14)$$

Bayesian Information Criterion for Summary Data

Based on Equation (3), we define the BIC for summary data:

$$\mathrm{BIC} = \log(\sigma_\alpha^2) + \frac{\log M}{M}\mathrm{df}, \quad (15)$$

where M is the number of IVs and df is the degree of freedom of the model[51]. In practice, σ_α^2 is

replaced by its empirical estimate $\hat{\sigma}_\alpha^2$, and df is the sum of non-zero causal effect estimates and

non-zero direct causal variant estimates. Our default setting assumes L can be 2,3,4,5,6,7, or 8

and uses BIC to select the optimal L among them. We found that when considering the

infinitesimal effect, it tends to capture variants with very small effects that SuSiE does not

identify, making it rare for L to exceed 8 in practice.

Pratt index

We use the Pratt index to assess the contribution of a gene-tissue pair. For a general linear

model: $y_i = \sum_{j=1}^{p} X_j \beta_j + \epsilon_i$, the Pratt index of x_{ij} is defined as $V_j = \beta_j \times b_j$, where $b_j =$

$\text{cov}(y, X_j)$. This definition assumes standardization where $E(y) = E(X_j) = 0$ and $\text{var}(y) =$

$\text{var}(X_j) = 1$, $1 \leq j \leq p$. The Pratt index measures the contribution of a variable in a linear

model because $R^2 = \sum_{j=1}^{p} V_j$ where $R^2 = \text{var}(\sum_{j=1}^{p} X_j \beta_j)/\text{var}(y)$. In practice, the Pratt index

can be estimated by $\hat{V}_j = \hat{\beta}_j \times \hat{b}_j$, where $\hat{b}_j$ is the sample correlation between X_j and y.

The proportion of variance explained (PVE) is defined as $PVE_j = \beta_j^2$, assuming that all variables

are standardized. The Pratt index has two key advantages over PVE: (1) Pratt indices are additive

across variables, and (2) the sum of Pratt indices is the total trait variance explained by

covariates. In contrast, PVE lacks these advantages.

Pratt Index in TGVIS

Wee show how to yield the Pratt index V_{jt} in practice. We first estimate the marginal correlation:

491
$$\tilde{\delta}_{jt} = \widehat{cor}(\widehat{\boldsymbol{\beta}}_{jt}, \widehat{\mathbf{a}}) = \frac{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}} \widehat{\mathbf{a}}}{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}} \mathbf{R} \widehat{\boldsymbol{\beta}}_{jt}} \sqrt{\widehat{\mathbf{a}}^{\mathsf{T}} \mathbf{R}^{-1} \widehat{\mathbf{a}}}}. \quad (16)$$

492   As for the causal effect estimate $\hat{\theta}_{jt}$, we apply the transformation

493
$$\tilde{\theta}_{jt} = \hat{\theta}_{jt} \frac{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}} \mathbf{R} \widehat{\boldsymbol{\beta}}_{jt}}}{\sqrt{\widehat{\mathbf{a}}^{\mathsf{T}} \mathbf{R}^{-1} \widehat{\mathbf{a}}}}, \quad (17)$$

494   since the Pratt index requires the covariates and trait are all standardized. Thus, the Pratt index of

495   the (j, t)th gene-tissue pair is

496
$$\hat{V}_{jt} = \tilde{\theta}_{jt} \times \tilde{\delta}_{jt} = \hat{\theta}_{jt} \frac{\hat{\boldsymbol{\beta}}_{jt}^{\top} \hat{\mathbf{a}}}{\hat{\mathbf{a}}^{\top} \mathbf{R}^{-1} \hat{\mathbf{a}}}. \quad (18)$$

497   Since Pratt indices are additive, the Pratt index of a credible set is simply calculated as

498
$$\hat{V}_{cs_l} = \sum_{j \in cs_l} \hat{V}_j. \quad (19)$$

499   Note that the Pratt index is only comparable within the same locus, as it represents the ratio of

500   the variance explained by the variable to the total variance of the trait.

501   It is worth comparing the gene-tissue pair, direct causal variant, and infinitesimal effect

502   contributions at a locus. To simplify the estimation, we consider the linear predictors of all gene-

503   tissue pairs and pleiotropy:

504
$$\tilde{\boldsymbol{\eta}}_{\theta} = \mathbf{R}^{\frac{1}{2}} \hat{\mathbf{B}} \hat{\boldsymbol{\theta}}, \quad \tilde{\boldsymbol{\eta}}_{\gamma} = \mathbf{R}^{\frac{1}{2}} \hat{\boldsymbol{\gamma}}, \quad \tilde{\boldsymbol{\eta}}_{\upsilon} = \mathbf{R}^{\frac{1}{2}} \hat{\boldsymbol{\upsilon}}. \quad (20)$$

505   and $\tilde{\mathbf{a}} = \mathbf{R}^{-\frac{1}{2}} \hat{\mathbf{a}}$, where $\mathbf{R}^{-\frac{1}{2}}$ is specified to remove the correlations of $\hat{\mathbf{B}}$ and $\hat{\mathbf{a}}$. Then, the Pratt

506   indices for the gene-tissue pairs, direct causal variants, and infinitesimal effects are

507
$$\hat{V}_{\theta} = \frac{\tilde{\boldsymbol{\eta}}_{\theta}^{\top} \tilde{\mathbf{a}}}{\parallel \tilde{\mathbf{a}} \parallel_2^2}, \quad \hat{V}_{\gamma} = \frac{\tilde{\boldsymbol{\eta}}_{\gamma}^{\top} \tilde{\mathbf{a}}}{\parallel \tilde{\mathbf{a}} \parallel_2^2}, \quad \hat{V}_{\upsilon} = \frac{\tilde{\boldsymbol{\eta}}_{\upsilon}^{\top} \tilde{\mathbf{a}}}{\parallel \tilde{\mathbf{a}} \parallel_2^2}. \quad (21)$$

Threshold of Pratt index

We used the empirical data to determine the threshold for Pratt index to enhance the precision of

causal selection. Specifically, we employed K-means clustering with clusters to group the CS-

Pratt indices of all gene-tissue pairs and direct variants identified by TGVIS within the 95%

credible sets. We hypothesize that one cluster contains credible sets with smaller CS-Pratt

values, which are more likely to include falsely causal variables. Interestingly, regardless of

whether we focus on gene-tissue pairs, direct causal variants, or both, the minimum value in the

cluster with the larger centroid consistently remains at 0.15 (**Figure S34**). Consequently, we set

the threshold at CS-Pratt = 0.15 to prioritize the gene-tissue pairs and direct causal variants

identified by TGVIS, considering variables with CS-Pratt > 0.15 to have a higher likelihood of

being true causal.

Score test of variance of infinitesimal effects

In implementation, dynamically determining whether to consider the infinitesimal effect is a

clever empirical measure. Therefore, we apply the score test of the variance of the random effect

in the linear mixed model to test whether the variance of the infinitesimal effect is zero.

Specifically, we consider the following hypothesis testing problem:

$$\mathrm{H}_0\colon \sigma_v^2 = 0, \quad v.s. \quad \mathrm{H}_1\colon \sigma_v^2 > 0. \quad (22)$$

The testing statistics of this hypothesis test is constructed according to Zhang and Lin[52]. Let $\mathbf{A} =$

$\left(\mathbf{R}\widehat{\mathbf{B}}_{\mathcal{M}_\theta}, \mathbf{R}_{\mathcal{M}_\gamma} \right)$ and $\boldsymbol{\vartheta} = \left(\boldsymbol{\theta}_{\mathcal{M}_\theta}^{\mathsf{T}}, \boldsymbol{\gamma}_{\mathcal{M}_\gamma}^{\mathsf{T}} \right)^{\mathsf{T}}$. When $\sigma_v^2 = 0$ and $\sigma_v^2 > 0$, the covariance matrix of $\widehat{\boldsymbol{\alpha}} -$

$\mathbf{A}\boldsymbol{\vartheta}$ are

$$\mathrm{cov}(\widehat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta}) = \sigma_\alpha^2 \mathbf{R}, \quad \mathrm{cov}(\widehat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta}) = \sigma_\alpha^2 \mathbf{R} + \sigma_v^2 \mathbf{R}^2, \quad (23)$$

respectively. Similar to estimating σ_v, we replace σ_α^2 by 1 to avoid non-identifiability. The score

described in Zhang and Lin[52] defined the following three statistics:

$$u = \frac{1}{2} \parallel \widehat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta} \parallel_2^2, \qquad e = \frac{1}{2}\mathrm{tr}(\mathbf{P}\mathbf{R}^2), \qquad h = \frac{1}{2}\mathrm{tr}(\mathbf{P}\mathbf{R}^2\mathbf{P}\mathbf{R}^2), \quad (24)$$

where $\mathbf{P} = \mathbf{R}^{-1} - \mathbf{R}^{-1}\mathbf{A}(\mathbf{A}^{\mathsf{T}}\mathbf{R}^{-1}\mathbf{A})^{-1}\mathbf{A}^{\mathsf{T}}\mathbf{R}^{-1}$. Under the null hypothesis, $u \sim \kappa\chi_v^2$ where $\kappa =$

$h/(2e)$ and $v = 2e^2/h$. If the null hypothesis is accepted, we enforce $\mathbf{v}^{(s+1)} = 0$.

Statistical principle of infinitesimal effects

While unknown biological mechanisms may underlie infinitesimal effects, we discuss the

statistical mechanisms that could generate them. First, it has been gradually understood that even

within the same ethnic group, such as the European population, different subgroups may have

different genetic architectures, leading to different LD structures. Therefore, it is natural to

suspect that the LD structures of populations in the GTEx consortium and those in traits GWAS

differ, which results in

$$\mathrm{E}(\hat{\boldsymbol{\alpha}}) = \mathbf{R}_{\mathrm{Meta}}(\mathbf{B}\boldsymbol{\theta} + \boldsymbol{\gamma}), \quad \mathrm{E}(\hat{\mathbf{b}}_{jt}) = \mathbf{R}_{\mathrm{GTEx}}\boldsymbol{\beta}_{jt}. \quad (25)$$

When we try to estimate $\boldsymbol{\beta}_{jt}$ using $\mathbf{R}_{\mathrm{Meta}}$, then $\hat{\boldsymbol{\beta}}_{jt}$ is biased to $\boldsymbol{\beta}_{jt}$, which generates infinitesimal

effect $\mathbf{v} = \sum_{jt}(\boldsymbol{\beta}_{jt} - \hat{\boldsymbol{\beta}}_{jt})\theta_{jt}$. It should be noted that the small sample size in the GTEx

consortium can also cause biased eQTL effect estimates, resulting in the appearance of

infinitesimal effects. We show other possible sources of statistical principles raising infinitesimal

effects in **Supplementary Materials**.

cTWAS and TGFM programs

For cTWAS, since its software is designed to be user-friendly to practical projects, it involves

complex settings that are not ideal for simulations, such as requiring a reference panel in BED

format and a .db file of eQTL fine-mapping data. Therefore, we directly utilize the principles of

cTWAS to develop an R function that employs SuSiE for the first-stage selection of *cis-*

regulatory effects and the second-stage selection of causal and horizontally pleiotropic effects.

At the time of writing this paper, the TGFM software has not yet been released. Therefore, we

did not consider the first step of cTWAS to estimate two universal prior parameters using the EM

algorithm across all loci in the genome. Instead, we restrict cTWAS simulations to a single locus.

In addition, we applied the following setting for cTWAS, TGFM and TGVIS: for the prior

weight π in SuSiE, we applied $\pi = p^{-1}$ for gene-tissue pairs and $\pi = M^{-1}$ for variants, where

p represents the number of gene-tissue pairs and M the number of variants.

To improve computational efficiency, we applied a slightly different resampling scheme

compared the original TGFM. Specifically, we first resampled the eQTL effects from the

posterior for 25 times, calculated their mean as $\hat{\beta}_{jt}^{t_i}$ and used these means to estimate $\hat{\theta}^{t_i}$

and $\hat{\gamma}^{t_i}$. This procedure was repeated 100 times, recording the estimates and PIP for each

iteration. We then compute the mean of $t_1 \times t_2$ resampled eQTL effects, $\hat{\beta}_{jt}^{TGFM}$, and estimate the

empirical $\hat{\theta}^{TGFM}$ and $\hat{\gamma}^{TGFM}$. The PIPs of $\hat{\theta}^{TGFM}$ and $\hat{\gamma}^{TGFM}$ were taken as the empirical PIPs

given by SuSiE in each resampling iteration. Finally, we recorded the credible sets of variables

from the final step and calculated the PIPs and Pratt indices of credible sets by summing the

individual PIPs and Pratt indices of variables within each credible set.

Simulation Settings

We simulated 20 genes across 5 tissues, resulting in $p = 100$ gene-tissue pairs. Correlations were

simulated both within and between genes across tissue. The first and last gene-tissue pairs were

designated as causal, with effect sizes of $\theta_1 = 1$ and $\theta_{100} = -1$, respectively. The total number

of variants was $M = 400$, with only 1,2,3 or 4 of them being eQTLs with non-zero effects for

each gene-tissue pair, while the remaining variants were associated with the trait due to LD. We

set 4 different sample sizes for the eQTL data ($n_{eQTL} = 100, 200, 400, 800$) and a fixed trait

GWAS sample size $n_{trait} = 0.5M$. Infinitesimal effect were generated from a normal

distribution, and gene-tissue pairs, direct causal variants, and infinitesimal effects together were

set to explain the trait heritability. For example, when only gene-tissue pairs and infinitesimal

effects are present, they each explain 50% of the local heritability for the outcome. When all

three are present, each explains 33% of the local heritability for the outcome. The detailed

settings, along with corresponding R codes, are provided in Section 2 of the **Supplementary**

Materials.

GWAS summary data

We conducted a meta-analysis on a subset of the 45 metabolic and cardiovascular traits. The

publicly available data for these traits are listed in **Table S1**, while the MVP GWAS summary

statistics can be accessed through dbGAP under accession number phs001672.v7.p1. For the

pleiotropy traits of SBP and DBP, we applied the approach developed in Zhu et al.[32] using the

most recent GWAS summary statistics of SBP and DBP. To perform the meta-analysis, we used

METAL[53]. We performed the meta-analysis on the Z-scores, weighting by the sample sizes of

the meta-analysis datasets. For binary trait, we always use the effective sample size n_{eff}. We

used CHR:BP (in GRCH37) as the identifier.

EQTL summary data

We utilized bulk eQTL and sQTL summary statistics from 28 tissues provided by GTEx[12] (with

sample size N ranging from 34.4 (Lymphocytes) to 179.5 (Muscle Skeletal)), as well as

additional eQTL summary statistics from tubulointerstitial[33] (N=311), kidney glomerular[33]

(N=240), and islet[34] (N=420) tissues (**Table S2**).

Linkage Disequilibrium Reference Panel

Our study used variants from the UKBB project conducted by Neale's lab, which initially

includes 13 million SNPs. We selected approximately 9.3 million SNPs with a minor allele

frequency greater than 0.01 for our analysis. We also identified the top 9,620 unrelated

individuals from approximately 500,000 individuals in the UKBB (Field ID: 22828), consisting

of 5,205 females and 4,475 males. Data from these 9.3 million SNPs were extracted for these

individuals to construct our LD reference panel.

Clumping and Thresholding

We restricted the studied regions to those within 1MB of the genome-wide significant loci for

these traits. These loci were identified using the clumping and thresholding (C+T) method in

PLINK[54]: --clump-kb 1000, --clump-p1 5E-8, --clump-p2 5E-8, and --clump-r2 0.01.

We recommend using C+T to filter out variants in high LD, which prevents the inclusion of

numerous highly correlated or redundant variants in the analysis, which can unnecessarily

complicate the model and result in multiple credible sets consisting of these variants. We

evaluated the minimum P-value of each variant across gene-tissue pairs in eQTL/sQTL data. In

PLINK, we applied the C+T with the following parameters: --clump-kb 1000, --clump-p1 1E-5, -

-clump-p2 1E-5, and --clump-r2 0.5. Given that the true causal variant for a trait might not be

included in the eQTL/sQTL variants, we combined these variants with the top 10% of variants

based on $P < 5E-8$ and $r^2 < 0.5$ from the trait GWAS.

Removing gene-tissue pairs based on significance in S-Predixcan

We used the minimum P-value from S-Predixcan and our modifier to exclude eGenes/sGene

with $P > 0.05$. The primary goal of these filters is to eliminate redundant gene-tissue pairs,

thereby reducing the model's dimensionality. Note that a threshold of $P < 0.05$ is quite weak,

making it unlikely to induce winner's curse. It is reasonable to speculate that, for most loci with

genome-wide significant signals, there would be no causal gene-tissue pairs having $P > 0.05$ in

with a univariable TWAS for the outcome.

Searching causal gene-tissue pairs missed by univariable TWAS

623 We compared the causal gene-tissue pairs identified by TGVIS and TGFM with the significant

624 gene-tissue pairs identified by S-PrediXcan. We considered genes with $P < 0.05/20,000$ as

625 significant gene-tissue pairs in tissue specific S-PrediXcan analysis. We did not adjust for

626 number of tissues. We then searched the gene-tissue pairs identified by TGVIS or TGFM but

627 missed by S-PrediXcan.

Obtaining annotation scores from FAVOR and performing differential annotation tests

We combined the direct causal variants and xQTLs of causal gene-tissue pairs identified by

TGVIS or TGFM across all 45 traits into two separate files and uploaded them to the FAVOR

online platform[35] to obtain annotation scores for these variants. We performed Wilcoxon signed-

rank test with both "less" and "greater" as alternative hypotheses for determining the direction of

shift location and calculated corresponding P-values. We used the R package FDREstimation to

convert the P-values to FDR Q-values using the Benjamini–Yekutieli (BY) procedure.

Annotations with Q-values less than 0.05 were considered to have significantly different scores.

Mapping major trait relevant tissues

637 For TGVIS, a 95% credible set often includes multiple gene-tissue pairs. In such cases, we

638 calculated the proportion of each tissue appearing among these pairs, allowing the number of

639 tissues in a causal credible set of gene-tissue pairs to be fractional. For TGFM, we first removed

640   the gene-tissue pairs with PIPs < 0.5, and then applied the same procedure to map the dominant

641   tissues.

Enrichment of identified causal genes in lipids silver gene list and druggable gene database

We applied the following strategy to map silver genes. First, we checked each credible set to see

if any genes are part of the silver gene list; if so, we counted 1. If no silver gene was present, we

then checked if any genes in the credible set were among the nearby genes; if so, we also

counted 1. In other words, each credible set of gene-tissue pairs was counted only once. For

TGFM, we first removed the gene-tissue pairs with PIPs < 0.5, and then applied the same

procedure as TGVIS to count the silver and nearby genes. Similar to the mapping procedure for

silver genes, we examined each credible set identified as causal to see if it contained any

druggable genes. If a druggable gene is present, we count it once.

We used the following statistics to compare the enrichments of TGVIS and TGFM. For example,

regarding TGVIS and a given trait, we consider three metrics: the number of causal genes

identified by TGVIS, the overlap between genes identified by TGVIS and those in the drug-

target list, and the ratio of these two metrics (referred to as Ratio hereafter). To compare whether

TGVIS or TGFM had a higher enrichment across traits, we performed a paired t-test using two

vectors of Ratio.

Colocalization of credible sets

We use colocalization to evaluate the causal credible sets identified by TGFM and TGVIS.

Within each region, we select variants from the outcome GWAS with P-values less than 5E-5

and $r^2 < 0.81$ for colocalization analysis. We perform fine-mapping on both the outcome and the

gene-tissue pairs within credible sets using SuSiE, then calculate the posterior probability for

hypothesis H_4, i.e., both traits are associated and share the same single causal variant, between

each outcome and exposure pair using Coloc-SuSiE. We use a posterior probability of H_4 greater

than 0.5 as the threshold to determine colocalization evidence between gene-tissue pairs and the

outcome; notably, as long as at least one variant meets this criterion, it suffices.

Mendelian Randomization using pQTL summary data

We performed both univariable and multivariable MR using pQTLs of protein abundance as IVs

to evaluating the identified causal tissue-gene pairs. Because to the lack of tissue-specific protein

data, we focused on a subset of pGenes identified in blood tissues provided by Sun et al.[10]. We

selected independent, genome-wide significant pQTLs for each protein as IVs. The selection

method for independent IVs was C+T (--clump-kb 1000 --clump-p1 5e-8 --clump-p2 5e-8 --

clump-r2 0.01 using PLINK), with LD reference panels consisting of the 9,680 individuals and

9.3M variants from UKBB. We applied five univariable MR methods: MRMedian[55], IMRP[56],

MRCML[57], MRCUE[58], and MRBEE[59]. Both MRCUE and MRBEE account for sample overlap,

with sample overlap correlations estimated using insignifint variants. We used the R package

FDREstimation to convert the P-values obtained by these methods to FDR Q-values, using "BY"

as the adjustment method. A pGene was considered significant if it was identified as such by at

least four methods. We also conducted an analysis comparing the enrichments of TGVIS and

TGFM, where the three corresponding metrics are: the overlap between causal genes identified

by TGVIS or TGFM and the pGenes reported in Sun et al.[10], the number of significant pGenes

identified in univariable MR analysis, and the ratio of these two metrics.

Author contributions

Y.Y and X.Z conceived and designed the study. Y.Y. performed all analysis. Y.Y and X.Z.

drafted the manuscript. N.L. edited the manuscript. X.Z. supervised this project.

Acknowledgments

This work was supported by grant HG011052 and HG011052-03S1 (to X.Z.) from the National

Human Genome Research Institute (NHGRI), USA.

Declarations of interests

The authors declare no competing interests.

Ethics approval

The study was approved by the institutional review board (IRB number: STUDY20180592) at

Case Western Reserve University

Data Availability

The GWAS summary data, eQTL summary data, and pQTL summary data used in this study can

be downloaded from the "Data available" section of the literature listed in **Table S1-S2**. The

GTEx summary data can be obtained from https://gtexportal.org/home/downloads/adult-gtex/qtl.

The GWAS data in the million veteran program (MVP) are available through database of

genotypes and phenotypes (dbGAP) under accession number phs001672.v7.p1. The individual-

level data from the UKBB used for estimating the LD matrix was accessed through Application

ID: 81097.

Code Availability

The code for the analyses presented in this paper is available in the **Supplementary Materials**,

complete with step-by-step instructions. The TGVIS R package can be downloaded from

https://github.com/harryyiheyang/TGVIS.

References

1.   Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of

lipids. *Nature* **600**, 675–679 (2021).

2.   Yengo, L. *et al.* A saturated map of common genetic variants associated with human

height. *Nature* **610**, 704–712 (2022).

3.   Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.

Nature **627**, 347–357 (2024).

4.   Mostafavi, H., Spence, J. P., Naqvi, S. & Pritchard, J. K. Systematic differences in discovery

of genetic effects on gene expression and complex traits. *Nat. Genet.* **55**, 1866–1875

(2023).

5.   Wallace, C. A more accurate method for colocalisation analysis allowing for multiple

causal variants. *PLOS Genet.* **17**, e1009440 (2021).

6.   Gamazon, E. R. *et al.* A gene-based association method for mapping traits using

reference transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).

7.   Gkatzionis, A., Burgess, S. & Newcombe, P. J. Statistical methods for cis-Mendelian

randomization with two-sample summary-level data. *Genet. Epidemiol.* **47**, 3–25

(2023).

8.   Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association

studies. *Nat. Genet.* **51**, 592–599 (2019).

9.   Li, Y. I. *et al.* RNA splicing is a primary link between genetic variation and disease.

Science **352**, 600–604 (2016).

10. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK

Biobank. *Nature* **622**, 329–338 (2023).

11. Amariuta, T., Siewert-Rocks, K. & Price, A. L. Modeling tissue co-regulation estimates

tissue-specific contributions to disease. *Nat. Genet.* **55**, 1503–1511 (2023).

12. The GTEx Consortium *et al.* The GTEx Consortium atlas of genetic regulatory effects

across human tissues. *Science* **369**, 1318–1330 (2020).

13. Zhao, S. *et al.* Adjusting for genetic confounders in transcriptome-wide association

studies improves discovery of risk genes of complex traits. *Nat. Genet.* **56**, 336–347

(2024).

14. Strober, B. J., Zhang, M. J., Amariuta, T., Rossen, J. & Price, A. L. Fine-mapping causal

tissues and genes at disease-associated loci. Preprint at

https://doi.org/10.1101/2023.11.01.23297909 (2023).

15. Burgess, S. & Thompson, S. G. *Mendelian Randomization*. (Chapman and Hall/CRC,

2021). doi:10.1201/9780429324352.

16. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable

Selection in Regression, with Application to Genetic Fine Mapping. *J. R. Stat. Soc. Ser. B*

Stat. Methodol. **82**, 1273–1300 (2020).

17. Cui, R. *et al.* Improving fine-mapping by modeling infinitesimal effects. *Nat. Genet.* **56**,

162–169 (2024).

18. Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with

the "Sum of Single Effects" model. *PLOS Genet.* **18**, e1010299 (2022).

19. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from

genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).

20. Liang, Y., Nyasimi, F. & Im, H. K. On the problem of inflation in transcriptome-wide

association studies. Preprint at https://doi.org/10.1101/2023.10.17.562831 (2023).

21. Sidorenko, J. *et al.* Genetic architecture reconciles linkage and association studies of

complex traits. *Nat. Genet.* (2024) doi:10.1038/s41588-024-01940-2.

22. Wood, S. N. Fast Stable Restricted Maximum Likelihood and Marginal Likelihood

Estimation of Semiparametric Generalized Linear Models. *J. R. Stat. Soc. Ser. B Stat.*

Methodol. **73**, 3–36 (2011).

23. Aschard, H. A perspective on interaction effects in genetic association studies. *Genet.*

Epidemiol. **40**, 678–688 (2016).

24. Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial

fibrillation biology. *Nat. Genet.* **50**, 1234–1239 (2018).

25. Surendran, P. *et al.* Discovery of rare variants associated with blood pressure regulation

through meta-analysis of 1.3 million individuals. *Nat. Genet.* **52**, 1314–1332 (2020).

26. Sinnott-Armstrong, N. *et al.* Genetics of 35 blood and urine biomarkers in the UK

Biobank. *Nat. Genet.* **53**, 185–194 (2021).

27. Pazoki, R. *et al.* Genetic analysis in European ancestry individuals identifies 517 loci

associated with liver enzymes. *Nat. Commun.* **12**, 2579 (2021).

28. Young, W. J. *et al.* Genetic analyses of the electrocardiographic QT interval and its

components identify additional loci and pathways. *Nat. Commun.* **13**, 5144 (2022).

29. Ghouse, J. *et al.* Genome-wide meta-analysis identifies 93 risk loci and enables risk

prediction equivalent to monogenic forms of venous thromboembolism. *Nat. Genet.* **55**,

399–409 (2023).

30. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes

for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815

(2022).

31. Roychowdhury, T. *et al.* Genome-wide association meta-analysis identifies risk loci for

abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. *Nat. Genet.*

55, 1831–1842 (2023).

32. Zhu, X., Zhu, L., Wang, H., Cooper, R. S. & Chakravarti, A. Genome-wide pleiotropy

analysis identifies novel blood pressure variants and improves its polygenic risk scores.

Genet. Epidemiol. **46**, 105–121 (2022).

33. Han, S. K. *et al.* Mapping genomic regulation of kidney disease and traits through high-

resolution and interpretable eQTLs. *Nat. Commun.* **14**, 2229 (2023).

34. Viñuela, A. *et al.* Genetic variant effects on gene expression in human pancreatic islets

and their implications for T2D. *Nat. Commun.* **11**, 4912 (2020).

35. Zhou, H. *et al.* FAVOR: functional annotation of variants online resource and annotator

for variation across the human genome. *Nucleic Acids Res.* **51**, D1300–D1311 (2023).

36. Trajanoska, K. *et al.* From target discovery to clinical drug development with human

genetics. *Nature* **620**, 737–745 (2023).

37. GTEx Consortium *et al.* Estimating the causal tissues for complex traits and diseases.

Nat. Genet. **49**, 1676–1683 (2017).

38. Arvanitis, M., Tayeb, K., Strober, B. J. & Battle, A. Redefining tissue specificity of genetic

regulation of gene expression in the presence of allelic heterogeneity. *Am. J. Hum. Genet.*

109, 223–239 (2022).

39. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple

instrumental variables in Mendelian randomization: comparison of allele score and

summarized data methods. *Stat. Med.* **35**, 1880–1906 (2016).

40. Grant, A. J. & Burgess, S. An efficient and robust approach to Mendelian randomization

with measured pleiotropic effects in a high-dimensional setting. *Biostatistics* **23**, 609–

625 (2022).

41. Kirk, T., Ahmed, A. & Rognoni, E. Fibroblast Memory in Development, Homeostasis and

Disease. *Cells* **10**, 2840 (2021).

42. Wittich, H. *et al.* Transcriptome-wide association study of the plasma proteome reveals

cis and trans regulatory mechanisms underlying complex traits. *Am. J. Hum. Genet.* **111**,

445–455 (2024).

43. Ross, S. D. *et al.* Clinical Outcomes in Statin Treatment Trials: A Meta-analysis. *Arch.*

Intern. Med. **159**, 1793 (1999).

44. Xu, Y. *et al.* Rs7206790 and rs11644943 in FTO Gene Are Associated with Risk of

Obesity in Chinese School-Age Population. *PLoS ONE* **9**, e108050 (2014).

45. Campos, A. I. *et al.* Boosting the power of genome-wide association studies within and

across ancestries by using polygenic scores. *Nat. Genet.* **55**, 1769–1776 (2023).

46. Yang, Y., Zhu, X., Lee, D. & Chakravarti, A. Partitioning Tissue-Specific Heritability and

Identifying Tissue-Specific Causal Genes of Blood Pressure Traits Using Tissue-Specific

CRE Annotation. *Manuscript*.

47. Okamoto, J. *et al.* Probabilistic Fine-mapping of Putative Causal Genes. Preprint at

https://doi.org/10.1101/2024.10.27.620482 (2024).

48. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type–specific genetic control of

autoimmune disease. *Science* **376**, eabf3041 (2022).

49. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in

Humans. *N. Engl. J. Med.* **373**, 895–907 (2015).

50. Zhu, X. & Stephens, M. Bayesian large-scale multiple regression with summary statistics

from genome-wide association studies. *Ann. Appl. Stat.* **11**, (2017).

51. Schwarz, G. Estimating the dimension of a model. *Ann. Stat.* **6**, (1978).

52. Zhang, D. & Lin, X. Hypothesis testing in semiparametric additive mixed models.

Biostatistics **4**, 57–74 (2003).

53. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

54. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based

Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

55. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing

Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734–

1739 (2017).

56. Zhu, X., Li, X., Xu, R. & Wang, T. An iterative approach to detect pleiotropy and perform

Mendelian Randomization analysis using GWAS summary statistics. *Bioinformatics* **37**,

1390–1400 (2021).

57. Lin, Z., Xue, H. & Pan, W. Robust multivariable Mendelian randomization based on

constrained maximum likelihood. *Am. J. Hum. Genet.* **110**, 592–605 (2023).

58. Cheng, Q., Zhang, X., Chen, L. S. & Liu, J. Mendelian randomization accounting for

complex correlated horizontal pleiotropy while elucidating shared genetic etiology. *Nat.*

Commun. **13**, 6490 (2022).

59. Lorincz-Comi, N., Yang, Y., Li, G. & Zhu, X. MRBEE: A bias-corrected multivariable

Mendelian Randomization method. *Hum. Genet. Genomics Adv.* 100290 (2024)

doi:10.1016/j.xhgg.2024.100290.

Figure 1: Overview of TGVIS. **A**: A hypothetical causal diagram illustrating the relationships between variants (including xQTLs, direct causal variants, and non-causal variants), tissue-specific gene expressions, and an outcome in a *cis*-region, where the arrows indicate the flow of causal effects in the causal diagram. Variants may be in LD, with only a subset having cis-regulatory effects. Gene expressions or splicing events are tissue-specific and form a complex co-regulation network. Only molecular phenotypes directly connected to the outcome are considered causal. **B**: Locus-zoom plot of the LDL-C GWAS in the *PCSK9* locus. The bottom panel displays the coding regions of genes located within this locus, including *PCSK9*, *UPS24*, *BSND*, etc. **C**: Workflow of TGVIS, consisting of three main steps. (I) Input, including GWAS summary data, eQTL summary data from multiple tissues, and LD matrix. (II) Preprocessing, including eQTL selection and pre-screening. We applied S-Predixcan to pre-screen some noise pairs, aiming to reduce the dimension of the multivariable TWAS model to a reasonable scale. (III) Estimation, where TGVIS first selects the causal gene-tissue pairs and direct causal variants via SuSiE and then estimates the infinitesimal effect via REML. (IV) Output, including the causal effect estimate, direct causal effect estimate, and infinitesimal effect estimates. We output plots demonstrating the causal gene-tissue pairs, direct causal variants and predicted infinitesimal effects: (1) the Pratt indices and other statistics such as PIPs, estimates, SEs of causal gene-tissue pairs in the 95% credible sets, (2) the Pratt indices of the direct causal variants in the 95% credible sets, and (3) the best linear unbiased predictors of infinitesimal effects. The non-zero variance in output III in this figure suggests the non-zero contribution of infinitesimal effects.

Figure 2: Simulation results comparing the performances of TGVIS, TGFM, cTWAS, Grant2022, and *cis*IVW with xQTL sample size = 200. **A**: The MSE of causal effect estimates under no pleiotropy, in the presence of direct causal variants, infinitesimal effects, and both. **B**: The true negative rate of identifying all 98 non-causal gene-tissue pairs under different scenarios i.e., no pleiotropy, in the presence of direct causal variants, infinitesimal effects, and both. This is equivalent to that if a method incorrectly identifies any non-causal pairs as causal, it will not be counted as a true negative event. **C**: Bar plots display the true positive rates of identifying all 2 causal gene-tissue pairs under different scenarios. **D**: The averaged number of identified direct causal variants by the different methods. The number of true causal variants were set to 0, 2, 0, and 2 for no-pleiotropy, direct-causal-variant, infinitesimal-effects, and direct-causal-variant and infinitesimal-effects, respectively. **E**: The averaged correlation of the true and estimated direct causal effects across simulations. **F**: The averaged correlation of the true and predicted infinitesimal effects across simulations.

Figure 3: Summary of the identification of causal gene-tissue pairs and direct causal variants. **A-B**: The number and proportion of causal and likely novel causal gene-tissue pairs identified by TGVIS and TGFM, respectively. Likely novel gene-tissue pairs are defined as those not present in the list of significant gene-tissue pairs identified by univariable S-PrediXcan (P < 0.05/20000). The proportion refers to the average number of causal and likely novel causal gene-tissue pairs per locus. **C**: The number and proportion of direct causal variants identified by TGVIS and TGFM. **D**: The distribution of the number of traits affected by causal gene-tissue pairs. **E-F**: The distributions of scores for FathmmXF and Encode H3K9me3Sum annotations. Raincloud plots illustrate four classes: direct causal variants and xQTLs of causal gene-tissue pairs identified by TGVIS and TGFM. Pairwise Wilcoxon signed-rank test P-values are displayed at the top, while medians of annotation scores are shown at the bottom.

Figure 4: Genetic architecture inferred from the identification of causal gene-tissue pairs and direct causal variants. **A**: The ratio of identified causal gene-tissue pairs per credible set by TVGIS. Different gene-tissue pairs may share the same set of xQTLs, and end in the same credible set. **B**: The ratio of the number of causal eQTLs over the number of sQTLs per causal gene-tissue pair, indicating the distribution of eQTLs and sQTLs contributing to the gene-tissue pairs. **C**: The distribution of eGene and sGene in credible sets identified by TGVIS and TGFM. When a credible set contains multiple gene-tissue pairs, we calculate the proportion of eGenes and sGenes. **D**: The distribution of Pratt Index estimates for different traits, with a comparison between TGVIS and TGFM. In the boxplot, each point represents the Pratt Index of various molecular phenotypes within a single locus.

Figure 5: Distribution of major tissues for cardiometabolic traits. **A**: Heatmaps display the major tissues associated with each trait, identified by TGVIS. **B**: Heatmaps display the major tissues associated with each trait, identified by TGFM. The major gene-tissue pairs are cataloged based on stringent criteria (CS-Pratt > 0.15 for TGVIS and PIP > 0.5 for TGFM) and the proportions of major tissues derived from significant gene-tissue pairs for each trait are quantified. Hierarchical clustering is applied to arrange the heatmaps, utilizing the Ward2 method and Euclidean distance. **C**: Major tissues of lipid traits identified by TGVIS and TGFM. This panel shows bar plots detailing the number of causal gene-tissue pairs for various lipid traits, including HDL-C, LDL-C, TC, triglycerides, APOA1, and APOB, as identified by both TGVIS (top) and TGFM (bottom).

A. Proportions of causal credible sets with colocalization evidence

B. Number/Proportion of causal genes in FDA-approved drug-target gene list

C. Number/Proportion of genes significant in univariable MR analysis

Figure 6: Evaluation of identified gene-tissue pairs. **A**: The colocalized proportions of causal credible sets (under two criteria) yielded by TGVIS and TGFM, respectively. **B**: The numbers and proportions of causal cis-genes in the list of FDA-approved drug-target genes provided by Trajanoska et al., identified by TGVIS (left) and TGFM (right), respectively. **C**: The number of significant pGenes in univariable MR analysis and the ratio of significant pGene in univariable MR analysis divided by significant eGenes/sGenes in eQTL/sQTL analysis.

Figure 7: Locuszoom plots comparing the results of TGVIS and TGFM. **A-C**: LDL-C (*PCSK9* locus). **D-F**: LDL-C (*HMGCR* locus). **G-I**: CAD (*PHACTR1* locus), **K-L**: BMI (*FTO* locus). For each locus, we included three plots: (1) the GWAS of the trait, (2) the PIP of gene-tissue pairs and direct causal variants identified by the TGVIS and TGFM, and (3) the Pratt index of corresponding gene-tissue pairs and variants. For TGVIS, causality is determined by (1) the variables are in a 95% credible set and (2) the Pratt index of this credible set is larger 0.15. For TGFM, the causality is determined by (1) the individual PIP is larger than 0.5.